Magnetar Financial LLC Makes New Investment in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Magnetar Financial LLC acquired a new stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) during the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 6,501 shares of the biopharmaceutical company’s stock, valued at approximately $214,000.

A number of other hedge funds also recently made changes to their positions in the stock. Venturi Wealth Management LLC purchased a new stake in Agios Pharmaceuticals during the fourth quarter valued at about $33,000. Wingate Wealth Advisors Inc. bought a new stake in Agios Pharmaceuticals in the 4th quarter worth approximately $53,000. KBC Group NV boosted its stake in Agios Pharmaceuticals by 30.5% in the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock worth $86,000 after buying an additional 611 shares in the last quarter. Quest Partners LLC grew its position in Agios Pharmaceuticals by 139.6% during the third quarter. Quest Partners LLC now owns 2,202 shares of the biopharmaceutical company’s stock valued at $98,000 after acquiring an additional 1,283 shares during the last quarter. Finally, Quantbot Technologies LP purchased a new position in shares of Agios Pharmaceuticals during the third quarter worth approximately $146,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Royal Bank of Canada upped their price objective on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. HC Wainwright began coverage on Agios Pharmaceuticals in a research note on Monday, February 24th. They set a “buy” rating and a $58.00 price objective on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. Scotiabank increased their target price on Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a report on Monday, December 9th. Finally, StockNews.com cut Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 14th. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $56.57.

Agios Pharmaceuticals Price Performance

AGIO opened at $31.30 on Monday. Agios Pharmaceuticals, Inc. has a one year low of $27.14 and a one year high of $62.58. The business has a 50 day simple moving average of $33.38 and a two-hundred day simple moving average of $41.28. The firm has a market capitalization of $1.79 billion, a price-to-earnings ratio of 2.76 and a beta of 0.90.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing analysts’ consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. As a group, sell-side analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $32.18, for a total transaction of $90,232.72. Following the transaction, the insider now owns 18,906 shares in the company, valued at approximately $608,395.08. This represents a 12.92 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 4.93% of the company’s stock.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.